Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted): 2022-2025

Historic EPS (Weighted Average and Diluted) for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to -$0.15.

  • Silence Therapeutics' EPS (Weighted Average and Diluted) rose 40.00% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.15, marking a year-over-year increase of 45.95%. This contributed to the annual value of -$0.33 for FY2024, which is 32.65% up from last year.
  • Silence Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.15 in Q3 2025, which was up 21.05% from -$0.19 recorded in Q2 2025.
  • Silence Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.09 for Q4 2024, and its period low was -$0.25 during Q3 2024.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.15 (2025), whereas its average is -$0.12.
  • As far as peak fluctuations go, Silence Therapeutics' EPS (Weighted Average and Diluted) soared by 166.92% in 2024, and later plummeted by 900.00% in 2025.
  • Silence Therapeutics' EPS (Weighted Average and Diluted) (MRQ) stood at -$0.16 in 2022, then rose by 13.69% to -$0.13 in 2023, then surged by 166.92% to $0.09 in 2024, then tumbled by 266.67% to -$0.15 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.15 for Q3 2025, versus -$0.19 for Q2 2025 and -$0.20 for Q1 2025.